A multicenter study on the significance of IGRA screening for the diagnosis of latent tuberculosis infection in patients initiating hemodialysis

A multicenter study on the significance of IGRA screening for the diagnosis of latent tuberculosis infection in patients initiating hemodialysis - Latent tuberculosis infection in patients initiating hemodialysis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058182

Enrollment

800

Registered

2025-06-20

Start date

2023-10-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent tuberculosis infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: [Hemodialysis Group] Male and Female aged 50 to under 90 years who are newly initiated on hemodialysis and do not meet any exclusion criteria. [Control Group] Male and Female aged 50 to under 90 years who do not meet any exclusion criteria.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: These criteria specify reasonable grounds for excluding individuals from the study population who otherwise meet the inclusion criteria. 1) Individuals with a history of tuberculosis 2) Individuals who have previously received treatment for latent tuberculosis infection (LTBI) 3) Individuals with a household member diagnosed with active tuberculosis 4) Individuals in the control group with an estimated glomerular filtration rate (eGFR) <= 45 mL/min/1.73m2 5) Individuals in the control group who are receiving specialized outpatient care for kidney disease 6) Individuals in the hemodialysis group undergoing temporary dialysis initiation, such as continuous hemodiafiltration (CHDF)

Design outcomes

Primary

Measure	Time frame
Prevalence of latent tuberculosis infection (LTBI) in patients initiating hemodialysis	—

Countries

Japan

Contacts

Public ContactTomoki Nagasaka

Keio University School of Medicine, Department of Infectious Diseases

jsdt.vaccine.antibody@gmail.com+81-3-3353-1211

Outcome results